Development of a thyroid hormone receptor targeting conjugate

Bioconjugate Chemistry

Volumn 19, Issue 6, 2008, Pages 1227-1234

  Zheng, Jianfei ^a   Hashimoto, Atsushi ^a,b   Putnam, Marc ^a,c   Miller, Katherine ^a   Koh, John T ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c Hercules Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCRINOLOGY; PROBES; STEROID HORMONES;

CHEMICAL BIOLOGY; DIVERSE APPLICATIONS; FUNCTIONAL DOMAINS; HORMONE RECEPTORS; MOLECULAR PROBES; NATURAL LIGANDS; RECEPTOR LIGANDS; RECEPTOR TARGETING; STEROID HORMONE RECEPTORS; THYROID HORMONE RECEPTOR;

LIGANDS;

LIOTHYRONINE; THYROID HORMONE RECEPTOR;

ARTICLE; BINDING AFFINITY; CELL ASSAY; CONJUGATE; HORMONE SYNTHESIS; LIGAND BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PURIFICATION;

EID: 45749138858     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc8000326     Document Type: Article

References (30)

1. Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., and Crews, C. M. (2004) Chemical genetic control of protein levels: Selective in vivo targeted degradation. J. Am. Chem. Soc. 126, 3748-3754.
2. Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., and Deshaies, R. J. (2003) Development of protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2, 1350-1358.
3. Liu, B., Alluri, P. G., Yu, P., and Kodadek, T. (2005) A potent transactivation domain mimic with activity in living cells. J. Am. Chem. Soc. 127, 8254-8255.
4. Ohno, K., Fukushima, T., Santa, T., Waizumi, N., Tokuyama, H., Maeda, M., and Imai, K. (2002) Estrogen receptor binding assay method for endocrine disruptors using fluorescence polarization. Anal. Chem. 74, 4391-4396.
5. Chambliss, K. I., Kumar, P., Yuhanna, I. S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Chieko, M., and Shaul, P. W. (2006) Estrogen dendrimer conjugate reveals that estrogen-induced endothelial cell migration and proliferation are mediated by non-nuclear estrogen receptors that interact directly with G alpha i. Circulation 114, 157-157.
6. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758.
7. Pike, A. C., Brzozowski, A. M., Hubbard, R. E., Bonn, T., Thorsell, A. G., Engstrom, O., Ljunggren, J., Gustafsson, J. A., and Carlquist, M. (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18, 4608-4618.
8. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937.
9. Xu, H. E., Stanley, T. B., Montana, V. G., Lambert, M. H., Shearer, B. G., Cobb, J. E., McKee, D. D., Galardi, C. M., Plunket, K. D., Nolte, R. T., Parks, D. J., Moore, J. T., Kliewer, S. A., Willson, T. M., and Stimmel, J. B. (2002) Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR alpha. Nature 415, 813-817.
10. Weatherman, R. V., Fletterick, R. J., and Scanlan, T. S. (1999) Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 68, 559-581.
11. Nguyen, N. H., Apriletti, J. W., Lima, S. T. C., Webb, P., Baxter, J. D., and Scanlan, T. S. (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem. 45, 3310-3320.
12. Baxter, J. D., Goede, P., Apriletti, J. W., West, B. L., Feng, W. J., Mellstrom, K., Fletterick, R. J., Wagner, R. L., Kushner, P. J., Ribeiro, R. C. J., Webb, P., Scanlan, T. S., and Nilsson, S. (2002) Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 143, 517-524.
13. Yen, P. M. (2001) Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81, 1097-1142.
14. Yen, P. M., and Cheng, S. Y. (2003) Germline and somatic thyroid hormone receptor mutations in man. J. Endocrinol. Invest. 26, 780-787.
15. Cheng, S. Y. (2003) Thyroid hormone mutations in cancer. Mol. Cell. Endocrinol. 213, 23-30.
16. Hulbert, A. J. (2000) Thyroid hormones and their effects: a new perspective. Biol. Rev. 75, 519-631.
17. Kopp, P., Kitajima, K., and Jameson, J. L. (1996) Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Proc. Soc. Exp. Biol. Med. 211, 49-61.
18. Leeson, P. D., Emmett, J. C., Shah, V. P., Showell, G. A., Novelli, R., Prain, H. D., Benson, M. G., Ellis, D., Pearce, N. J., and Underwood, A. H. (1989) Selective thyromimetics-cardiac-sparing thyroid-hormone analogs containing 3′-arylmethyl substituents. J. Med. Chem. 32, 320-336.
19. Yokoyama, N., Walker, G. N., Main, A. J., Stanton, J. L., Morrissey, M. M., Boehm, C., Engle, A., Neubert, A. D., Wasvary, J. M., Stephan, Z. F., and Steele, R. E. (1995) Synthesis and structure-activity-relationships of oxamic acid and acetic-acid derivatives related to L-thyronine. J. Med. Chem. 38, 695-707.
20. Borngraeber, S., Budny, M. J., Chiellini, G., Cunha-Lima, S. T., Togashi, M., Webb, P., Baxter, J. D., Scanlan, T. S., and Fletterick, R. J. (2003) Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. U.S.A. 100, 15358-15363.
21. Chiellini, G., Nguyen, N. H., Yoshihara, H. A. I., and Scanlan, T. S. (2000) Improved synthesis of the iodine-free thyromimetic GC-1. Bioorg. Med. Chem. Lett. 10, 2607-2611.
22. Shi, Y., Ye, H., Link, K. H., Putnam, M. C., Hubner, I., Dowdel, S., and Koh, J. T. (2005) Mutant-selective thyromimetics for the chemical rescue of thyroid hormone mutants associated with resistance to thyroid hormone (RTH). Biochem. J. 44, 4612-4626.
23. Miyoshi, Y., Nakamura, H., Sasaki, S., Tagami, T., Misaki, T., Konishi, J., and Nakao, K. (1995) Two consecutive nucleotide substitutions resulting in the T3 receptor beta gene resulting in an 11-amino acid truncation in a patient with generalized resistance to thyroid hormone. Mol. Cell. Endocrinol. 114, 9-17.
24. Taniyama, M., Kusano, S., Miyoshi, Y., Nakamura, H., Kaihara, M., Tobe, T., Tomita, M., Katagiri, T., and Ban, Y. (1996) Mild resistance to thyroid hormone with a truncated thyroid hormone receptor beta. Exp. Clin. Endocrinol. Diabetes 104, 339-343.
25. i determined by nonlinear regression of single run ± 95% confidence interval.
26. Nguyen, N. H., Apriletti, J. W., Baxter, J. D., and Scanlan, T. S. (2005) Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. J. Am. Chem. Soc. 127, 4599-4608.
27. Malm, J., Gordon, S., Brandt, P., Carlsson, B., Agback, P., Saeidi, A. B., and Sandberg, J. (2007) Thyroid receptor ligands. Bioorg. Med. Chem. 17, 2018-2021.
28. Dow, R. L., Schneider, S. R., Paight, E. S., Hank, R. F., Chiang, P., Cornelius, P., Lee, E., Newsome, W. P., Swick, A. G., Spitzer, J., Hargrove, D. M., Patterson, T. A., Pandit, J., Chrunyk, B. A., LeMotte, P. K., Danley, D. E., Rosner, M. H., Ammirati, M. J., Simons, S. P., Schulte, G. K., Tate, B. F., and DaSilva-Jardine, P. (2003) Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: Potent, TR beta subtypeselective thyromimetics. Bioorg. Med. Chem. Lett. 13, 379-382.
29. Koehler, K., Gordon, S., Brandt, P., Carlsson, B., Backsbro-Saeidi, A., Apelqvist, T., Agback, P., Grover, G. J., Nelson, W., Grynfarb, M., Farnegardh, M., Rehnmark, S., and Malm, J. (2006) Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. J. Med. Chem. 49, 6635-6637.
30. Komatsu, T., Hirano, T., Songkram, C., Kawachi, E., and Kagechika, H. (2007) Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. Bioorg. Med. Chem. 15, 3115-3126.